A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer

@article{OConnor2007API,
  title={A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer},
  author={Tracey L. O’Connor and Youcef M. Rustum and Edward H. Levine and Patrick J. Creaven},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2007},
  volume={61},
  pages={125-131}
}
There is a need for chemotherapy regimens active against anthracycline- and taxane-refractory breast cancer. Data from preclinical and pilot studies performed at Roswell Park Cancer Institute (RPCI) suggested that when irinotecan (IRN) is given with 5-fluorouracil (5-FU) efficacy is affected by the sequence of drug administration. Pretreatment with IRN 24 h before 5-FU increased the number of tumor cells in S-phase and the antitumor activity in a preclinical system. These data provided the… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2004
View 3 Excerpts
Highly Influenced

Cancer statistics, 2006.

CA: a cancer journal for clinicians • 2006

Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1992
View 1 Excerpt

Similar Papers

Loading similar papers…